Successful pregnancy after administration of thymosin alpha-1 in a woman with recurrent implantation failure
Abstract
Recurrent Implantation Failure (RIF) poses a significant challenge in the management of infertility. We report a novel approach using Thymosin alpha 1 (TA 1) in a 32-year-old female with unexplained RIF. Despite previous failed IVF attempts and various interventions, including endometriosis treatment, ovarian platelet rich plasma therapy and Oocyte Donor (OD)-ICSI cycles along with other adjuvant therapies such as intralipids, steroids, low molecular weight heparin (LMWH), Hydroxychloroquine (HCQ), still pregnancy remained elusive. Immuno-profiling revealed Type 1 T helper cells (TH1) dominance, leading to TA 1 therapy alongside Hormone Replacement Therapy (HRT). TA 1, known for immune modulation, was administered as 13 injections before embryo transfer. Patient achieved a successful pregnancy, indicating TA 1 potential in immune-mediated RIF cases. Thymosin alpha’s safety and efficacy in pregnancy warrants further investigation through prospective trials for broader validation.
How this paper connects to the literature. Drag to explore, click any node to open that paper.
